News

May 29, 2012

Endo Announces Resolution of Patent Litigation with Watson Pharmaceuticals related to Lidoderm® – Agreement protects Lidoderm® and eliminates uncertainty

Endo Announces Resolution of Patent Litigation with Watson Pharmaceuticals related to Lidoderm® – Agreement protects Lidoderm® and eliminates uncertainty

Endo (Nasdaq: ENDP) announced on May 29, 2012 that it reached a settlement with Watson Pharmaceuticals (Watson) which resolved two patent infringement lawsuits related to Lidoderm®.

Endo’s President and CEO, Dave Holveck stated “We are pleased to have reached an agreement that protects Endo’s intellectual property interests and eliminates the uncertainty of a court decision.” and “We believe this agreement will benefit consumers and resolving this issue is another step forward in establishing Endo as the dynamic, diversified healthcare solutions company that we are today.”

Click here to view the press release in its’ entirety.


About Teikoku Pharma USA

Teikoku Pharma USA, Inc., a wholly-owned subsidiary of Teikoku Seiyaku Co., Ltd., is a specialty pharmaceutical company that develops and manufactures enhanced pharmaceutical products with its transdermal drug delivery technology and the developer and maker of the leading topical analgesic transdermal patch – Lidoderm®, Teikoku focuses its efforts on two therapeutic areas: chronic and acute pain, and the central nervous system (CNS). Committed to applying its transdermal technology for the benefit of patients and partners, the company looks forward to exploring new fields of use for its proprietary systemic transdermal patch.

Contact Us:
Teikoku Pharma USA, Inc.
Phone: +1-408-501-1800
Email